 | |
| Clinical data | |
|---|---|
| Other names | CDMA; Halodrol; Halodrol-50 |
| Routes of administration | Oral[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H29ClO2 |
| Molar mass | 336.90 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Chlorodehydromethylandrostenediol (CDMA), also known as4-chloro-17α-methylandrost-1,4-diene-3β,17β-diol, is asynthetic,orally activeanabolic-androgenic steroid (AAS) and a17α-alkylatedderivative of4-androstenediol that was never marketed.[1] It was first encountered in 2005 when it was introduced as a "dietary supplement" and putativeprohormone under the nameHalodrol-50 by industry veteran, Bruce Kneller while working with the dietary supplement company, Gaspari Nutrition.[1][2] The drug was the subject of a scathing and highly critical article byThe Washington Post in November 2006.[1] CDMA was voluntarily discontinued by Gaspari Nutrition in mid-2006, likely fearing government sanctions if it continued to sell the product.[1] During the brief period of time that CDMA was sold online, it was an extremely well-selling product; its total sales are estimated to have been greater than twenty five million dollars, and by some estimates, CDMA may have been the best-selling hormonal product ever sold "over-the-counter" (i.e., without aprescription) in theUnited States.[1]CDMA continued to be sold online until the 2014 prohormone ban as generic versions known as clones.
Although CDMA was sold as a "prohormone" or "prosteroid" ofchlorodehydromethyltestosterone (CDMT), it is likely that the conversion is far from complete and that much of the activity of the drug may be attributable to its unchanged form.[1] Due to the presence of achloro group at the C4 position, CDMA cannot bearomatized, and for this reason, poses no risk ofestrogenicside effects likegynecomastia at anydosage.[1] It is not extensivelymetabolized by5α-reductase and exhibits relatively greateranabolic thanandrogenic activity, but is still capable of producing androgenic side effects likeoily skin,acne, and increased growth offacial andbody hair, as well asvirilization in women.[1] As with other 17α-alkylated AAS, CDMA poses a risk ofhepatotoxicity.[1][3]
CDMA is closely related tochloromethylandrostenediol (CMA; Promagnon), which was also developed by industry veteran Bruce Kneller and was also briefly sold on theInternet in 2005 and 2006, though by a different company (Peak Performance Laboratories).[1] Both compounds were derived from CDMT (brand name Oral Turinabol), a popular AAS that was introduced in the 1960s.[1]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |